Analyst: New Novo Nordisk data sets the bar high for diabetes pills
Despite promising results, one analyst thinks patients will have to wait for higher doses of diabetes pill Rybelsus until 2025.
by marketwire, translated by daniel pedersen
On Friday, Novo Nordisk presented results from a phase IIIb trial called Pioneer Plus, in which oral semaglutide was tested in two high doses.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
